Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.

The systematic literature review informing the 2023 EULAR update found high-quality randomized evidence supporting anifrolumab in non-renal lupus and belimumab and voclosporin in lupus nephritis, and confirmed that attaining remission or low disease activity improves long-term outcomes.